🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Using Light Therapy for Mild Cognitive Impairment

RecruitingNAAges 55 Years - 95 YearsAllUniversity of Oklahoma
NCT07651787 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in people with mild cognitive impairment (MCI). The main questions it aims to answer are: * Does tPBM enhance cognitive function and cerebral hemodynamic responses during memory and finger tapping tasks? * Does tPBM reduce oxidative stress, inflammation, and mitigate brain cell damage? * Is cognitive improvement linked to amyloid status, greater cerebral hemodynamic response, and lower levels of brain inflammation and oxidative stress? Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation. Partici

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age: 55-95 years of age * Clinical Dementia Rating (CDR) equal to 0.5 and/or Montreal Cognitive Assessment (MoCA) \<26 and ≥19 * Adequate hearing and visual acuity to participate in the examinations * English speaker * Presence of cerebrovascular pathology confirmed by structural brain imaging method Exclusion Criteria: * Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer * Cerebrovascular accident other than TIA within 60 days prior to Visit 0 * Diagnosis of amyloid angiopathy * Major psychiatric disease, including major depression not controlled on medications, alcohol or drug abuse * Neurodegenerative diseases, e.g: Parkinson's, any kind of dementia * Patients currently using commercial brain stimulation / neuromodulation device as part of a research study * Patients currently take dietary supplements with an expected cerebrovascular benefit such as NAD- or NR-supplementum, L-citrullin, urolithin * Unstable medical condition, including uncontrolled diabetes, chronic heart issues, heart failure, chronic obstructive pulmonary disease, hypertension uncontrolled by medication (\>160/100 mmHg) * Any other medical condition or medication which, in the opinion of investigator, would render the patient too unstable to complete the study protocol * Severe sensory deficits interfering with the testing
💊

What it tests

  • Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation
  • Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
📍

Where

1 site
University of Oklahoma Health Campus
Oklahoma City, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy